摘要
目的评价弥可保治疗糖尿病缺血性视神经病变的疗效和安全性。方法将42例(60眼)糖尿病缺血性视神经病变病人随机分为两组。治疗组20例(30眼)采用弥可保500μg联合100 mg维生素B1肌肉注射,每天1次,10次为1个疗程,3个疗程后改为口服弥可保500μg和100 mg维生素B1,连用30 d;对照组22例(30眼)采用500μg维生素B12联合100 mg维生素B1肌肉注射,每天1次,10次为1个疗程,3个疗程后改为口服腺苷钴胺片500μg和100 mg维生素B1,连用30 d。观察治疗前后视力、眼底及视野变化。结果治疗组疗效明显优于对照组(u=3.716,P<0.01)。结论弥可保治疗糖尿病缺血性视神经病变是一种安全、有效的方法。
Objective To evaluate the efficacy and safety of Methycobal in the treatment of diabetic ischemic optic neuropathy（DION）. Methods Forty-two patients（60 eyes） with DION were randomly divided into treatment group and control group.The treatment group included 20 patients（30 diseased eyes） who were treated by cotherapy of I.M.of 500 μg of Methycobal and 100 mg of vitamin B1,once a day,for 30 days,and then altered to oral Methycobal and vitamin B1,same doses and days of medication;the control group consisted of 22 patients（30 diseased eyes）,cotherapy with vitamin B12（500 μg） and vitamin B1（100 mg）,I.M.,once a day,for 30 days,and then altered to oral Cobamamide tablets（500 μg） and vitamin B1（100 mg）,once a day for 30 days.Vision,fundus of eye,and visual field were examined before and after therapy. Results The therapeutic efficacy in the treatment group was significantly superior to that in the control（u=3.716,P0.01）. Conclusion Methycobal is safe and effective in the treatment of diabetic ischemic optic neuropathy.
出处
《齐鲁医学杂志》
2011年第3期259-260,共2页
Medical Journal of Qilu
关键词
弥可保
糖尿病
视神经病变
缺血性
治疗结果
Methycobal
diabetes mellitus
optic neuropathy
ischemic
treatment outcome
